114 related articles for article (PubMed ID: 38237714)
1. Investigation of co-treatment multi-targeting approaches in breast cancer cell lines.
Longaray JB; Dias CK; Scholl JN; Battastini AMO; Figueiró F
Eur J Pharmacol; 2024 Mar; 966():176328. PubMed ID: 38237714
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
3. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
[TBL] [Abstract][Full Text] [Related]
4. MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel.
Rasoolnezhad M; Safaralizadeh R; Hosseinpour Feizi MA; Banan-Khojasteh SM; Roshani Asl E; Lotfinejad P; Baradaran B
Mol Biol Rep; 2023 Oct; 50(10):8407-8420. PubMed ID: 37620737
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells.
Wawruszak A; Luszczki J; Czerwonka A; Okon E; Stepulak A
Cells; 2022 Apr; 11(7):. PubMed ID: 35406775
[TBL] [Abstract][Full Text] [Related]
6. ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.
Sarkar S; Mazumdar A; Dash R; Sarkar D; Fisher PB; Mandal M
J Cell Physiol; 2011 Feb; 226(2):375-84. PubMed ID: 20665703
[TBL] [Abstract][Full Text] [Related]
7. The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer.
Dastmalchi N; Azarbarzin S; Safaralizadeh R; Khojasteh SMB; Shadbad MA; Amini M; Baghbanzadeh A; Asl ER; Baghbani E; Lotfinejad P; Baradaran B
Med Oncol; 2021 Nov; 39(1):9. PubMed ID: 34761351
[TBL] [Abstract][Full Text] [Related]
8. Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.
Wawruszak A; Okon E; Telejko I; Czerwonka A; Luszczki J
Pharmacol Rep; 2022 Oct; 74(5):1011-1024. PubMed ID: 35900723
[TBL] [Abstract][Full Text] [Related]
9. The Curcumin Analog PAC Is a Potential Solution for the Treatment of Triple-Negative Breast Cancer by Modulating the Gene Expression of DNA Repair Pathways.
Almalki E; Al-Amri A; Alrashed R; Al-Zharani M; Semlali A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298600
[TBL] [Abstract][Full Text] [Related]
10. Effects of ecto-5'-nucleotidase on human breast cancer cell growth in vitro and in vivo.
Zhou X; Zhi X; Zhou P; Chen S; Zhao F; Shao Z; Ou Z; Yin L
Oncol Rep; 2007 Jun; 17(6):1341-6. PubMed ID: 17487388
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.
Jeansonne DP; Koh GY; Zhang F; Kirk-Ballard H; Wolff L; Liu D; Eilertsen K; Liu Z
Oncol Rep; 2011 May; 25(5):1473-80. PubMed ID: 21331447
[TBL] [Abstract][Full Text] [Related]
12. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells.
Huang MB; Gonzalez RR; Lillard J; Bond VC
Oncotarget; 2017 Feb; 8(7):11302-11315. PubMed ID: 28076321
[TBL] [Abstract][Full Text] [Related]
13. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
Li Y; Zhang L; Dong Z; Xu H; Yan L; Wang W; Yang Q; Chen C
Pathol Res Pract; 2021 Apr; 220():153405. PubMed ID: 33756128
[TBL] [Abstract][Full Text] [Related]
15. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
16. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
18. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells.
Ajabnoor GM; Crook T; Coley HM
Cell Death Dis; 2012 Jan; 3(1):e260. PubMed ID: 22278287
[TBL] [Abstract][Full Text] [Related]
20. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
Tohkayomatee R; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
Molecules; 2022 May; 27(11):. PubMed ID: 35684480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
